Dolasteron 多拉司琼
CAS 115956-12-2 MFCD15956122
化学结构图
SMILES: O=C1C[N@@]2[C@@H]3CC1C[C@H]2C[C@H](C3)OC(=O)c1c[nH]c2ccccc12
化学属性
| Mol. Formula | C19H20N2O3 |
|---|---|
| Mol. Weight | 324 |
别名和识别编码
| Chemical Name | Dolasteron |
|---|---|
| Synonym | 多拉司琼中间体 |
| InChIKey | UKTAZPQNNNJVKR-MMUVGSQPSA-N |
| Chemical Name Translation | 多拉司琼 |
| MDL Number | |
| CAS Number | 115956-12-2 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Schwartzberg L, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014 Feb;22(2):469-77.
- [1]. Faria C, et al. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014 Jan;7(1):50-8.
- [1]. Faria C, et al. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014 Jan;7(1):50-8.
- [2]. Schwartzberg L, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014 Feb;22(2):469-77.
